Forte Biosciences Inc Ordinary Shares FBRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $44.99
- Day Range
- $42.00–50.00
- 52-Week Range
- $9.10–50.00
- Bid/Ask
- $48.93 / $52.88
- Shares Outstanding
- 20.48M
- Market Cap
- $1.00B
- Volume/Avg
- 595,918 / 461,766
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 22
- Website
- https://www.fortebiorx.com
Valuation
|
Metric
|
FBRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 16.14 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
FBRX
Financial Strength
|
Metric
|
FBRX
|
|---|---|
Quick Ratio | 2.49 |
Current Ratio | 2.75 |
Interest Coverage | — |
Quick Ratio
FBRX
Profitability
|
Metric
|
FBRX
|
|---|---|
Return on Assets (Normalized) | −84.56% |
Return on Equity (Normalized) | −104.93% |
Return on Invested Capital (Normalized) | −104.93% |
Return on Assets
FBRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&$x<Q! | LOCK|VnR!R | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?m^<cD | LOCK|gQ@D< | $71B | |||
| argenx SE ADR
ARGX
| LOCK|NK$>&rC | LOCK|rhR | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^^m&<r | LOCK|!S | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?cLgT@ | LOCK|>kpB | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|gc>?kfM& | LOCK|>^g! | $26B | |||
| Moderna Inc
MRNA
| LOCK|W<gjJx | LOCK|#% | $25B | |||
| Incyte Corp
INCY
| LOCK|wF%P?L | LOCK|V>F | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Y@ZHlM | LOCK|nv | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|SG!X>$! | LOCK|tQ | $16B |
United States